Suppr超能文献

使用超高效液相色谱-四极杆飞行时间质谱联用技术对血浆中硫酸吲哚酚和3-羧基-4-甲基-5-丙基-2-呋喃丙酸进行超灵敏定量分析。

Ultra-Sensitive Quantification of Indoxyl Sulfate and 3-Carboxy-4-Methyl-5-Propyl-2-Furanpropanoic Acid in Plasma Using Ultra-Performance Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry.

作者信息

Negami Jun, Suzuki Yosuke, Sato Haruki, Toyama Daiki, Oda Ayako, Tanaka Ryota, Ono Hiroyuki, Ando Tadasuke, Shin Toshitaka, Itoh Hiroki, Ohno Keiko

机构信息

Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.

Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.

出版信息

J Clin Lab Anal. 2025 Aug;39(16):e70077. doi: 10.1002/jcla.70077. Epub 2025 Jul 11.

Abstract

BACKGROUND

Uremic toxins such as indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) are accumulated in patients with chronic kidney disease (CKD). Recent studies have shown that the accumulation of indoxyl sulfate and CMPF alters the activity of organic anion transporting polypeptide (OATP) 1B and cytochrome P450 (CYP) 3A, respectively. We established and validated a novel ultra-sensitive method for simultaneous quantification of indoxyl sulfate and CMPF using ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS).

METHOD

In this method, plasma samples were prepared by solid phase extraction, then analyzed by UPLC-QTOF/MS to measure concentrations of analytes. Using only 5 μL of human plasma per assay, the calibration range was 0.05-200 μg/mL and the lower limit of quantification was 0.05 μg/mL for both indoxyl sulfate and CMPF.

RESULTS

This assay met the acceptance criteria of the U.S. Food and Drug Administration bioanalytical method validation guidance. The clinical applicability of this assay was evaluated by measuring plasma concentrations in healthy volunteers and CKD patients. All measured concentrations were within the calibration range.

CONCLUSION

Our novel assay may contribute to the estimation of variation of OATP1B and CYP3A activities in patients, including those with CKD.

摘要

背景

尿毒症毒素如硫酸吲哚酚和3 - 羧基 - 4 - 甲基 - 5 - 丙基 - 2 - 呋喃丙酸(CMPF)在慢性肾脏病(CKD)患者体内蓄积。最近的研究表明,硫酸吲哚酚和CMPF的蓄积分别改变了有机阴离子转运多肽(OATP)1B和细胞色素P450(CYP)3A的活性。我们建立并验证了一种使用超高效液相色谱 - 四极杆飞行时间质谱联用仪(UPLC - QTOF/MS)同时定量硫酸吲哚酚和CMPF的新型超灵敏方法。

方法

在该方法中,血浆样本通过固相萃取制备,然后用UPLC - QTOF/MS分析以测量分析物浓度。每次测定仅使用5μL人血浆,硫酸吲哚酚和CMPF的校准范围均为0.05 - 200μg/mL,定量下限均为0.05μg/mL。

结果

该检测方法符合美国食品药品监督管理局生物分析方法验证指南的验收标准。通过测量健康志愿者和CKD患者的血浆浓度评估了该检测方法的临床适用性。所有测量浓度均在校准范围内。

结论

我们的新型检测方法可能有助于评估患者(包括CKD患者)中OATP1B和CYP3A活性的变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d6/12378369/6507396d202d/JCLA-39-e70077-g004.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验